Literature DB >> 11241324

Quantitative p21(waf-1)/p53 immunohistochemical analysis defines groups of primary invasive breast carcinomas with different prognostic indicators.

C Ceccarelli1, D Santini, P Chieco, C Lanciotti, M Taffurelli, G Paladini, D Marrano.   

Abstract

We used image cytometry to quantify the immunohistochemical expression of p21(waf-1) and p53 in primary breast carcinoma. Ratio analysis of the quantified p53/p21(waf-1) protein expression allowed us to define 3 groups of carcinomas, each characterized by specific pathological and biological profiles. The negative (NEG) group, characterized by negligible expression of both proteins, comprised small-sized, low-grade tumors associated with high contents of hormonal receptors and low growth fraction. In the NEG group, Ki-67 labelling index area (%LIa) was the only significant prognostic indicator. The P53H group, characterized by prevalence of p53 %LIa, was constituted by large-sized, high-grade tumors showing low hormonal receptor contents and high growth fraction. In the P53H group, both p53 and Ki-67 were inversely associated with both estrogen receptor (ER) and progesterone receptor (PGR), suggesting that extensive p53 immunostaining is related to poor differentiation and high proliferation. Only N status was prognostically significant in the P53H group. The P21H group, characterized by prevalence of p21(waf-1) %LIa, displayed intermediate pathological and biological features. A significant association between p53 and p21(waf-1) expression suggested functional stabilization of wtp53 and therefore possible DNA damage-dependent G1/S arrest (genetic instability) in the P21H group; P21(waf-1)expression was significantly associated with the presence of node metastasis. Patients in the P21H group had a higher recurrence rate and a shorter disease-free time interval from surgery with respect to the NEG group. Proportional hazard regression analysis disclosed Ki-67 %LIa and, to a lesser degree, PGR %LIa as significant relapse-free survival prognostic indicators. Copyright 2001 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11241324     DOI: 10.1002/1097-0215(20010320)95:2<128::aid-ijc1022>3.0.co;2-d

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  12 in total

1.  The opposite prognostic significance of nuclear and cytoplasmic p21 expression in resectable gastric cancer patients.

Authors:  Yefei Huang; Weimin Wang; Yansu Chen; Yulin Huang; Jianbing Zhang; Song He; Yongfei Tan; Fulin Qiang; Aiping Li; Oluf Dimitri Røe; Shouyu Wang; Yan Zhou; Jianwei Zhou
Journal:  J Gastroenterol       Date:  2013-10-15       Impact factor: 7.527

2.  Molecular signatures for CCN1, p21 and p27 in progressive mantle cell lymphoma.

Authors:  Afak Rasheed Salman Zaidi; Sadie Dresman; Charlotte Burt; Simon Rule; Lynn McCallum
Journal:  J Cell Commun Signal       Date:  2018-11-21       Impact factor: 5.782

3.  Distinction between hereditary and sporadic breast cancer on the basis of clinicopathological data.

Authors:  P van der Groep; A Bouter; R van der Zanden; I Siccama; F H Menko; J J P Gille; C van Kalken; E van der Wall; R H M Verheijen; P J van Diest
Journal:  J Clin Pathol       Date:  2006-04-07       Impact factor: 3.411

4.  Expression of cell cycle proteins in male breast carcinoma.

Authors:  Rani Kanthan; Isabella Fried; Theresa Rueckl; Jenna-Lynn Senger; Selliah Chandra Kanthan
Journal:  World J Surg Oncol       Date:  2010-02-12       Impact factor: 2.754

5.  p21WAF1 expression in invasive breast cancer and its association with p53, AP-2, cell proliferation, and prognosis.

Authors:  M J Pellikainen; T T Pekola; K M Ropponen; V V Kataja; J K Kellokoski; M J Eskelinen; V-M Kosma
Journal:  J Clin Pathol       Date:  2003-03       Impact factor: 3.411

6.  Predictive value of measuring p53 labeling index at the invasive front of oral squamous cell carcinomas.

Authors:  Koroku Kato; Shuichi Kawashiri; Akira Tanaka; Natsuyo Noguchi; Hiromitsu Nakaya; Takashi Hase; Etsuhide Yamamoto
Journal:  Pathol Oncol Res       Date:  2008-03-19       Impact factor: 3.201

7.  Cytoplasmic p21 is a potential predictor for cisplatin sensitivity in ovarian cancer.

Authors:  Xi Xia; Quanfu Ma; Xiao Li; Teng Ji; Pingbo Chen; Hongbin Xu; Kezhen Li; Yong Fang; Danhui Weng; Yanjie Weng; Shujie Liao; Zhiqiang Han; Ronghua Liu; Tao Zhu; Shixuan Wang; Gang Xu; Li Meng; Jianfeng Zhou; Ding Ma
Journal:  BMC Cancer       Date:  2011-09-21       Impact factor: 4.430

8.  Tumor suppression by miR-31 in esophageal carcinoma is p21-dependent.

Authors:  Zhifeng Ning; Hua Zhu; Feifei Li; Qing Liu; Gefei Liu; Tao Tan; Bo Zhang; Shaobin Chen; Guanwu Li; Dongyang Huang; Stephen J Meltzer; Hao Zhang
Journal:  Genes Cancer       Date:  2014-11

9.  Somatic cell type specific gene transfer reveals a tumor-promoting function for p21(Waf1/Cip1).

Authors:  Yuhui Liu; Nancy Yeh; Xin-Hua Zhu; Margaret Leversha; Carlos Cordon-Cardo; Ronald Ghossein; Bhuvanesh Singh; Eric Holland; Andrew Koff
Journal:  EMBO J       Date:  2007-10-18       Impact factor: 11.598

10.  TRIM3, a tumor suppressor linked to regulation of p21(Waf1/Cip1.).

Authors:  Y Liu; R Raheja; N Yeh; D Ciznadija; A M Pedraza; T Ozawa; E Hukkelhoven; H Erdjument-Bromage; P Tempst; N P Gauthier; C Brennan; E C Holland; A Koff
Journal:  Oncogene       Date:  2013-01-14       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.